Levetiracetam Eignapharma

Levetiracetam, the active ingredient in Levetiracetam Eignapharma, is an anticonvulsant presented as an injectable solution for intravenous use. It is employed as adjunctive therapy to control partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients requiring additional seizure management.

GNH USA supplies Levetiracetam Eignapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that acts on seizure activity across several seizure types. - Partial‑onset seizures: used as adjunctive therapy to reduce seizure frequency. - Generalized tonic‑clonic seizures: used as adjunctive therapy to help achieve better seizure control. - Myoclonic seizures: used as adjunctive therapy to decrease the number of seizure episodes.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate head pain. - Irritability: mood changes including agitation. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Suicidal ideation: thoughts of self‑harm that must be reported promptly. - Severe depression: marked mood disturbances that may need psychiatric evaluation. - Anaphylaxis: acute allergic reaction with breathing difficulty. - Blood dyscrasias: rare blood cell abnormalities such as leukopenia.

When prescribing levetiracetam, several safety considerations should be observed. - Renal impairment: adjust dosage according to renal function as recommended by the prescriber. - Hepatic impairment: monitor liver function tests periodically. - Pregnancy: category B; use only if the potential benefit justifies the potential risk to the fetus. - Concomitant CNS depressants: observe for enhanced sedation or respiratory depression. - Psychiatric symptoms: watch for mood changes, depression, or suicidal thoughts. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations, reducing efficacy. - Phenobarbital or phenytoin: enzyme‑inducing antiepileptics can decrease levetiracetam levels. - Strong CYP450 inhibitors: although levetiracetam is minimally metabolized, monitor for unexpected changes.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): may increase sedation and respiratory depression. - Other antiepileptic drugs: dose adjustments may be required to maintain seizure control. - Hormonal contraceptives: levetiracetam may reduce contraceptive effectiveness; consider alternative methods.